Laurion Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurion Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.34M	Buy	+4,706	New	+$2.09M	0.06%	204
2026 Q1	–	Sell	-2,200	Closed	-$997K	–	506
2025 Q4	$997K	Buy	+2,200	New	+$948K	0.04%	131
2024 Q3	–	Sell	-1,248	Closed	-$585K	–	604
2024 Q2	$585K	Sell	1,248 -65,645	-98%	-$28.5M	0.01%	344
2024 Q1	$28M	Buy	+66,893	New	+$28.3M	0.24%	91
2022 Q4	–	Sell	-705	Closed	-$204K	–	557
2022 Q3	$204K	Buy	+705	New	+$203K	﹤0.01%	435
2022 Q2	–	Sell	-11,949	Closed	-$3.12M	–	715
2022 Q1	$3.12M	Buy	+11,949	New	+$2.84M	0.04%	182
2020 Q4	–	Sell	-73,975	Closed	-$20.1M	–	996
2020 Q3	$20.1M	Buy	+73,975	New	+$20.4M	0.24%	102
2019 Q4	–	Sell	-2,675	Closed	-$453K	–	1264
2019 Q3	$453K	Buy	+2,675	New	+$473K	﹤0.01%	785
2017 Q4	–	Sell	-5,700	Closed	-$867K	–	1881
2017 Q3	$867K	Sell	5,700 -16,882	-75%	-$2.54M	﹤0.01%	1022
2017 Q2	$2.91M	Sell	22,582 -235,800	-91%	-$28.4M	0.02%	688
2017 Q1	$28.3M	Buy	+258,382	New	+$22.7M	0.21%	115
2015 Q3	–	Sell	-2,417	Closed	-$298K	–	918
2015 Q2	$298K	Buy	+2,417	New	+$305K	﹤0.01%	528

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Laurion Capital Management's VRTX Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 4,706 shares worth $2.34M. The stake represents 0.06% of the portfolio and ranks #204 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in VRTX as recently as Q4 2025.

Laurion Capital Management first reported a position in VRTX in Q2 2015 and has held it in 12 quarters since. The position peaked at $28.3M in Q1 2017. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Laurion Capital Management held 4,706 shares of Vertex Pharmaceuticals worth $2.34M as of Q2 2026.
Vertex Pharmaceuticals was a new Laurion Capital Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.06% of Laurion Capital Management's portfolio in Q2 2026, its #204 holding.
Laurion Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 12 quarters since.
Laurion Capital Management's Vertex Pharmaceuticals position peaked at $28.3M in Q1 2017.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.